

BET  
4-28-02  
#  
6/IOS

In regard to the application of: Nissim DARVISH, et al.

Serial No: 09/914,889

Group Art Unit: To be assigned

I. A. Filing Date: March 5, 2000

Examiner: To be assigned

For: BLOOD GLUCOSE LEVEL CONTROL

RECEIVED

INFORMATION DISCLOSURE STATEMENT MAR X 7 2002

Hon. Commissioner of Patents and Trademarks

TECHNOLOGY CENTER #3700

Washington, DC 20231

Sir:

Applicants respectfully direct the attention of the Examiner to art cited with respect to PCT/IL00/00132 of which the current application is a US national application under 35 USC section 371.

The Examiner is respectfully requested to review and consider this art, in accordance with MPEP 2001.06, MPEP 1893.03(e) and MPEP 1893.03(g) and to indicate in the first office action that he has considered this art. Additionally, the Examiner is respectfully requested to cite those prior art publications mentioned in this application which the Examiner considers to be material or relevant to the present claims.

Further, in order to comply with discretionary regulations 37 CFR 1.97 and 1.98, attached is Form PTO-1449 listing the cited art. Also attached are copies<sup>1</sup> of the art. This art contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent. Items 5-8 were cited on the PCT International Search Report. Copies of these items are not attached as they are available in the national stage file.

In accordance with MPEP Section 609 it is requested that each document cited (including any mentioned in Applicant's specification which is not repeated on the attached PTO-1449 form) be given thorough consideration and that it be cited of record in the

---

<sup>1</sup> To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the national stage file. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such an equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited then none is known to the undersigned.

prosecution history of the present application by initialing on the PTO-1449 form, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not believe that the guidelines for citation have been fully complied with.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37CFR 1.104(a), and in the course of such search will review for relevance every document cited on the attached form.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,  
Nissim DARVISH, et al.

A handwritten signature in black ink, appearing to read 'Maier Fenster', written over a horizontal line.

Maier FENSTER,  
Registration No. 41,016

December 26, 2001

William H. Dippert, Esq.  
Cowan, Liebowitz and Latman, P.C.  
1133 Avenue of the Americas  
New York, NY 10036-6799  
Tel: (212) 790-9200



I hereby certify that this correspondence is being deposited  
with the United States Postal Service as first class mail in  
an envelope addressed: BOX MISSING PARTS, Commissioner of Patents  
and Trademarks, Washington, D.C. 20231, on ----December 27, 2001 -----  
Date of Deposit

William H. Dippert

Attorney

A handwritten signature in cursive script, appearing to read "William H. Dippert".

Signature

December 27, 2001

Date of Signature

The Commissioner is hereby authorized to charge any additional fee which  
may be required, or credit any overpayment to Account No. 03-3415.

RECEIVED

MAR X 7 2002

TECHNOLOGY CENTER R3700

3737 0432


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
015/02367

In Re Application of: Nissim DARVISH, et al.

37E/

FEB 21 2002



Serial No.

**I.A**

Filing Date

March 5, 2000

Examiner

Unknown

Group Art Unit

Not yet assigned

**RECEIVED**

Title: **BLOOD GLUCOSE LEVEL CONTROL**

MAR X 7 2002

TECHNOLOGY CENTER R3700

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).